A study led by researchers at Karolinska Institutet analyzed national health registry data from Sweden, Denmark, and Norway involving more than 280,000 patients with type 2 diabetes treated with SGLT2 inhibitors. ^[1] Patients with type 2 diabetes who have high blood glucose levels, low body weight, or a history of ketoacidosis are at increased risk of developing ketoacidosis when treated with SGLT2 inhibitors. ^[2] Infection was identified as the most common triggering or co-occurring event in cases of ketoacidosis among patients taking SGLT2 inhibitors. ^[3] The study showed that the risk of ketoacidosis remains elevated throughout the entire course of treatment, not just during the initial stages. ^[4] Artificial intelligence can now analyze millions of chemical compounds and identify therapeutic molecules, reducing drug discovery times that historically required years and billions of dollars. ^[5] Cardiovascular diseases remain the leading cause of death worldwide, with over 20.5 million deaths per year, according to the World Heart Federation. ^[6] The author argues that the pharmaceutical industry is solving the wrong problem by focusing on diagnosis and treatment rather than prevention. ^[7] The author proposes that the next step is to build systems capable of continuous patient accompaniment using wearables, remote monitoring, and AI to intervene when habits are forming. ^[8]